比较flt3-itd阳性与阴性急性髓细胞白血病的实验室特征及疗效-to compare the laboratory characteristics and efficacy of flt 3 - itd positive and negative acute myeloid leukemia.docxVIP

Comparison of molecular biology and immunological characteristics and clinical efficacy of the patients inacute myelogenous leukemia with or without FLT3-ITD gene mutationAbstractObjectiveAcute myeloid leukemia is the most important part of hematologic malignancies, the incidence rate showed an upward trend. Unfortunately, its pathogenesis is not yet fully understood, mainly from cytogenetics, molecular biology and immunology performance to learn it ,so that classification criteria, treatment methods and prognosis indicators are also constantly correct. Cytogenetics were identified as independent prognostic indicators,but large amounts of data show that about 45% of AML patients with normal karyotype, prognosis evaluation of them rely on molecular biology features. Therefore, the significance of gene’s detection is very clearly, especially the early warning meaning to patients who recived complete remission.Today’s clinical test results showed: FLT3 (FMS-like receptor tyrosine kinase 3) and NPM1 (Nucleophosmin) are the most frequent mutated gene in AML.FLT3, becauseofitsnegativeeffectonpatients,gainsmoreattentionsfrom researchers.However, the comparative analysis of clinical and laboratory characteristics, Clinical efficacy and prognosis is still wanting.This paper summarized the clinical features, immunology, cytogenetics, molecular biology, therapeutic effect and prognosis of newly diagnosed patients with or without FLT3-ITD mutation, to explore the gene systematically.Methods Retrospective analysis of 93 novol AML patients, aged from 10 to 66 years, were joined in this study in which 21 patients who had FLT3-ITD gene expression were assined to FLT3-ITD_group, and other 72 patients who had no FLT3-ITD gene expressionwere assined to control_group. Cytogenetic studies and the gene mutatations of FLT3-ITD，NPM1 and others were analyzed.Results Among the 93 patients, 22.58% of them expressed FLT3